MT2A is an early predictive biomarker of response to chemotherapy and a potential therapeutic target in osteosarcoma.

ABSTRACT: Osteosarcoma is the most prevalent primary bone malignancy in children and young adults. Resistance to chemotherapy remains a key challenge for effective treatment of patients with osteosarcoma. The aim of the present study was to investigate the preventive role of metallothionein-2A (MT2A) in response to cytotoxic effects of chemotherapy. A panel of human and murine osteosarcoma cell lines, modified for MT2A were evaluated for cell viability, and motility (wound healing assay). Cell-derived xenograft models were established in mice. FFPE tumour samples were assessed by IHC. In vitro experiments indicated a positive correlation between half-maximal inhibitory concentration (IC50) for drugs in clinical practice, and MT2A mRNA level. This reinforced our previously reported correlation betwee

SUBMITTER: Mangelinck A 

PROVIDER: S-EPMC6707240 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature